Form 4: Theravance Biopharma Director Reports Acquisition and Disposal of Shares
SEC Form 4 Filing
Director Eran Broshy reports acquisition of shares and disposal of shares in Theravance Biopharma, Inc.
Summary
- On May 8, 2024, Eran Broshy, a director of Theravance Biopharma, Inc., reported transactions involving the company's ordinary shares and share options.
- Broshy acquired 10,537 ordinary shares at $0 and disposed of 80,555 ordinary shares.
- Following these transactions, Broshy beneficially owns 80,555 ordinary shares.
- Broshy also acquired 23,576 share options with an exercise price of $9.49, exercisable from May 8, 2024, to May 7, 2034.
- These options vest in monthly installments with any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors monitor these filings to gain insights into management's perspective on the company's stock.
Stakeholder Impact
- The transactions may be of interest to shareholders as they provide insight into the actions of a company director.
Key Dates
| Date | Description |
|---|---|
| 05/08/2024 | Date of transaction for ordinary shares and share options |
| 05/07/2034 | Expiration date of share options |
| 05/10/2024 | Date of signature for the report |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.